URGN · ISSUER CIK 1668243
UroGen Pharma Ltd.
Between Aug 1, 2026 and Oct 29, 2026, 4 UroGen Pharma Ltd. insiders reported $0.00 of open-market purchases and $3.0M of sales on SEC Form 4.
↗4 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 0 of 4 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$3.0MInsider selling
−$3.0MNet open-market
Oct 9, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 9, 202612:57 | Oct 8, 2026 | URGN | Chief Financial Officer | S · Sell | $36.69 | −2,202 | 4,561 | -33% | −$81K | ||
| Oct 9, 202612:57 | Oct 8, 2026 | URGN | Chief Financial Officer | M · Exercise | — | +4,483 | 6,763 | +197% | — | ||
| Sep 9, 202614:37 | Sep 8, 2026 | URGN | Chief Medical Officer | S · Sell | $42.92 | −871 | 59,882 | -1% | −$37K | ||
| Sep 9, 202614:37 | Sep 7, 2026 | URGN | Chief Medical Officer | M · Exercise | — | +1,667 | 60,753 | +3% | — | ||
| Sep 9, 202614:35 | Sep 8, 2026 | URGN | General Counsel | S · Sell | $42.54 | −1,519 | 53,141 | -3% | −$65K | ||
| Sep 9, 202614:35 | Sep 7, 2026 | URGN | General Counsel | M · Exercise | — | +3,334 | 54,660 | +6% | — | ||
| Aug 28, 202616:01 | Aug 26, 2026 | URGN | Director | M · Exercise | — | +2,000 | 8,000 | +33% | — | ||
| Aug 24, 202617:03 | Aug 20, 2026 | URGN | Chief Medical Officer | S · Sell | $47.05 | −60,677 | 59,086 | -51% | −$2.9M |